Publication Listing for the MeSH term Gemcitabine. Found 7 abstracts
Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2019 Jul 23;. |
Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee SJ, Bedrick E, Du R, Lee FC. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer medicine. 2017 Sep;6(9):2042-51. PMCID: PMC5603839 |
Cohen SJ, O'Neil BH, Berlin J, Ames P, McKinley M, Horan J, Catalano PM, Davies A, Weekes CD, Leichman L. A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study. Cancer Chemother Pharmacol. 2016 Feb 17;77(4):693-701. |
Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD. Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Eur J Cancer. 2015 Jul 14;51(14):1857-64. |
Movsas B, Langer CJ, Ross HJ, Wang LH, Jotte RM, Feigenberg S, Xu F, Huang CH, Monberg MJ, Obasaju CK. Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2010 May;5(5):673-9. PMCID: not NIH funded |
Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, MacAlpine K, Wright JJ, Oza AM. Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer A Study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer. 2010 Jul;20(5):787-93. PMCID: Not required |
Lilenbaum R, Villaflor VM, Langer C, O'Byrne K, O'Brien M, Ross HJ, Socinski M, Oldham FB, Sandilac L, Singer JW, Bonomi P. Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials. Journal of Thoracic Oncology. 2009 Jan;4(7):869-74. PMCID: not NIH funded |
MeSH cloud from publications including the MeSH term Gemcitabine
Gemcitabine
Nab-paclitaxel
Erlotinib
Pancreatic cancer
NSCLC
Vinorelbine
Metastatic pancreatic adenocarcinoma
paclitaxel
Combination
Oxaliplatin
trial
Clivatuzumab tetraxetan
STELLAR
Consolidation
oncology
Phase 1b
bevacizumab
Combination chemotherapy
Bile Duct Cancer
renal-cell carcinoma
solid tumors
Sorafenib
radiotherapy
Paclitaxel poliglumex
CA125
primary peritoneal
Docetaxel
chemotherapy
Antibody
Vantictumab
Prognostic model
angiogenesis
therapy
guidelines
B
Performance status 2
platinum
Radioimmunotherapy
progression
concurrent
Yttrium-90
Antiangiogenic
sequential chemoradiotherapy
Ovarian cancer
surgery
Stage IIIA
Single-agent chemotherapy
Hcc